Market capitalization | $90.00k |
Enterprise Value | $-5.81m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.58 |
EV/Sales (TTM) EV/Sales | -290.50 |
P/S ratio (TTM) P/S ratio | 4.50 |
P/B ratio (TTM) P/B ratio | 0.02 |
Revenue growth (TTM) Revenue growth | -99.50% |
Revenue (TTM) Revenue | $20.00k |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast Histogen Inc:
1 Analyst has issued a forecast Histogen Inc:
Sep '23 |
+/-
%
|
||
Revenue | 0.02 0.02 |
99%
99%
|
|
Gross Profit | -0.16 -0.16 |
104%
104%
|
|
EBITDA | -12 -12 |
-
|
EBIT (Operating Income) EBIT | -12 -12 |
12%
12%
|
Net Profit | -12 -12 |
15%
15%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Histogen, Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. The company engages in research, development, and manufacturing of products derived from its technology. It offers an insoluble human extracellular matrix (hECM); and a soluble complex of proteins. The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. It has joint venture with PUR Biologics, Adaptive Biologix, and Histogen Aesthetics to develop additional products. Histogen, Inc. was founded in 2007 and is based in San Diego, California.
Head office | United States |
CEO | Susan Knudson |
Founded | 2005 |
Website | www.histogen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.